Anokion raises $40M series B, grabs back programs from spinout

Alongside raising $40 million in a series B round, autoimmune company Anokion said Wednesday it will acquire Kanyos Bio, a company it spun out and partnered with Astellas in 2015.

Versant Ventures, Novartis Venture Fund, Novo Ventures,

Read the full 362 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE